Howard Capital Management Inc. Increases Position in DexCom, Inc. (NASDAQ:DXCM)

Howard Capital Management Inc. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,921 shares of the medical device company’s stock after purchasing an additional 317 shares during the period. Howard Capital Management Inc.’s holdings in DexCom were worth $849,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC raised its stake in DexCom by 2.2% in the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after buying an additional 214,136 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after acquiring an additional 710,858 shares during the last quarter. Groupama Asset Managment raised its position in shares of DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after purchasing an additional 288,381 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on DXCM. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Wells Fargo & Company raised their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Citigroup upped their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $99.06.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,083 shares of company stock worth $3,309,794. Company insiders own 0.30% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $88.78 on Monday. The stock has a market capitalization of $34.69 billion, a P/E ratio of 62.08, a P/E/G ratio of 2.30 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company’s fifty day moving average is $83.50 and its two-hundred day moving average is $76.06.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.